Aetna, Humana officially kill merger

Health insurers Aetna and Humana have mutually ended their $37 billion merger agreement two weeks after a federal judge blocked the deal on antitrust grounds.

At the time, Aetna publicly said it was considering an appeal of the ruling. Instead, it will pay a $1 billion break-up fee to Humana (amounting to about $630 million after taxes) and drop the case.

“While we continue to believe that a combined company would create greater value for healthcare consumers through improved affordability and quality, the current environment makes it too challenging to continue pursuing the transaction,” Aetna Chairman and CEO Mark Bertolini said in a statement. “We are disappointed to take this course of action after 19 months of planning, but both companies need to move forward with their respective strategies in order to continue to meet member expectations.”

Aetna is also calling off a sale of Medicare Advantage assets to Molina, a move that was designed to assuage concerns about the Humana deal’s anticompetitive impact on the Medicare Advantage market.

Those arguments, like all in Aetna’s case defending the merger, didn’t sway U.S. District Judge John Bates. In his Jan. 23 ruling, he said the merger would eliminate “valuable head-to-head competition” and doubted customers would see savings from the deal.

“It is very likely that a significant share of the claimed efficiencies may be retained by the merged firm rather than being passed on to consumers,” Bates wrote.

Aetna didn’t say whether the termination of the deal affects its business plans for the Affordable Care Act exchanges in 2018 and beyond. The court ruling said Aetna’s decision to reduce its participation in 2017 was motivated in part by the federal government’s antitrust lawsuit. In a Jan. 31 conference call, Bertolini said the company had “no intention” of being in the insurance marketplace for 2018.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup